Bajaj Healthcare informs about press release

04 Oct 2025 Evaluate
Bajaj Healthcare has informed that the company has received recommendation from Subject Expert Committee (SEC) (Neurology & Psychiatry) of Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Suvorexant Tablets 5mg, 10mg, 50mg, 15mg & 20mg. The press release in this regard, being issued by the Company is submitted.

The above information is a part of company’s filings submitted to BSE. 

Bajaj Healthcare Share Price

345.95 -1.10 (-0.32%)
01-Feb-2026 12:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.80
Dr. Reddys Lab 1225.15
Cipla 1315.10
Zydus Lifesciences 881.80
Lupin 2115.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×